Ken Griffin's Citadel added 2.7 million AbbVie shares in the second quarter, lifting the hedge fund's position by 547 percent to 3.2 million shares valued at roughly $798 million. The stake now represents 0.46 percent of the portfolio, a meaningful allocation to a single name for a multi-strategy fund that typically spreads risk across thousands of positions. The 13F filing dated August 14 shows the build coincided with a broader de-risking effort that included unwinding 80 percent of the assets Citadel had acquired from the AI-focused Situational Awareness fund at a discount.
The dividend king thesis
AbbVie qualifies as a Dividend King with 54 consecutive years of payout increases, a streak that includes its years as part of Abbott Laboratories before the 2012 spin-off. The company paid a third-quarter dividend of $1.73 per share in mid-August, yielding 2.6 percent at current levels. Operating cash flow rose 7 percent year over year to $7.3 billion, providing ample coverage. The portfolio also holds a roster of blockbuster drugs, Rinvoq, Skyrizi, Vraylar, Botox, Qulipta and Ubrelvy, and has been acquiring pipeline assets in immunology, oncology, obesity and neuroscience.
Valuation optics
The headline price-to-earnings ratio sits at 74, but that figure is distorted by acquisition-related charges over the trailing twelve months. The forward multiple is 18 and the five-year PEG ratio is 0.47, a level that typically signals the stock is cheap relative to expected earnings growth. Since the filing, shares have climbed from about $249 to roughly $264, a 6 percent move that leaves the stock up 16 percent year to date. The median analyst price target of $282.50 implies another 7 percent of upside over the next twelve months, and 75 percent of covering analysts rate the stock a buy.
What the move actually signals
Griffin told investors, according to CNBC, that he executed roughly 100 block trades worth more than $4 billion in total to de-risk the portfolio and lock in profits. The AbbVie purchase fits that narrative: a large, liquid, defensive name with a durable payout and a cash-flow profile that can withstand a market downdraft. Whether the allocation reflects genuine conviction or simply a place to park capital while equity valuations sit at historic highs is the question the next 13F will help answer.